PubMed:12634320 JSONTXT

Annnotations TAB JSON ListView MergeView

    Glycan-Motif

    {"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":666,"end":675},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T2","span":{"begin":666,"end":675},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T3","span":{"begin":832,"end":841},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T4","span":{"begin":832,"end":841},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T5","span":{"begin":956,"end":965},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T6","span":{"begin":956,"end":965},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T7","span":{"begin":1077,"end":1086},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T8","span":{"begin":1077,"end":1086},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T9","span":{"begin":1204,"end":1213},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T10","span":{"begin":1204,"end":1213},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T11","span":{"begin":1709,"end":1718},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T12","span":{"begin":1709,"end":1718},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlyCosmos6-Glycan-Motif-Image

    {"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":666,"end":675},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":832,"end":841},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":956,"end":965},"obj":"Glycan_Motif"},{"id":"T7","span":{"begin":1077,"end":1086},"obj":"Glycan_Motif"},{"id":"T9","span":{"begin":1204,"end":1213},"obj":"Glycan_Motif"},{"id":"T11","span":{"begin":1709,"end":1718},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A4","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A6","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"},{"id":"A7","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A8","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"},{"id":"A9","pred":"image","subj":"T9","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A10","pred":"image","subj":"T9","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"},{"id":"A11","pred":"image","subj":"T11","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G68158BT"},{"id":"A12","pred":"image","subj":"T11","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlyCosmos6-Glycan-Motif-Structure

    {"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":666,"end":675},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T2","span":{"begin":666,"end":675},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T3","span":{"begin":832,"end":841},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T4","span":{"begin":832,"end":841},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T5","span":{"begin":956,"end":965},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T6","span":{"begin":956,"end":965},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T7","span":{"begin":1077,"end":1086},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T8","span":{"begin":1077,"end":1086},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T9","span":{"begin":1204,"end":1213},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T10","span":{"begin":1204,"end":1213},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"},{"id":"T11","span":{"begin":1709,"end":1718},"obj":"https://glytoucan.org/Structures/Glycans/G65889KE"},{"id":"T12","span":{"begin":1709,"end":1718},"obj":"https://glytoucan.org/Structures/Glycans/G68158BT"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":105,"end":387},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":388,"end":585},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":586,"end":731},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":732,"end":873},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":874,"end":1019},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1020,"end":1214},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1215,"end":1405},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1406,"end":1548},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1549,"end":1554},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1555,"end":1694},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1695,"end":1848},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T2","span":{"begin":105,"end":387},"obj":"Sentence"},{"id":"T3","span":{"begin":388,"end":585},"obj":"Sentence"},{"id":"T4","span":{"begin":586,"end":731},"obj":"Sentence"},{"id":"T5","span":{"begin":732,"end":873},"obj":"Sentence"},{"id":"T6","span":{"begin":874,"end":1019},"obj":"Sentence"},{"id":"T7","span":{"begin":1020,"end":1214},"obj":"Sentence"},{"id":"T8","span":{"begin":1215,"end":1405},"obj":"Sentence"},{"id":"T9","span":{"begin":1406,"end":1694},"obj":"Sentence"},{"id":"T10","span":{"begin":1695,"end":1848},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T2","span":{"begin":105,"end":387},"obj":"Sentence"},{"id":"T3","span":{"begin":388,"end":585},"obj":"Sentence"},{"id":"T4","span":{"begin":586,"end":731},"obj":"Sentence"},{"id":"T5","span":{"begin":732,"end":873},"obj":"Sentence"},{"id":"T6","span":{"begin":874,"end":1019},"obj":"Sentence"},{"id":"T7","span":{"begin":1020,"end":1214},"obj":"Sentence"},{"id":"T8","span":{"begin":1215,"end":1405},"obj":"Sentence"},{"id":"T9","span":{"begin":1406,"end":1548},"obj":"Sentence"},{"id":"T10","span":{"begin":1549,"end":1554},"obj":"Sentence"},{"id":"T11","span":{"begin":1555,"end":1694},"obj":"Sentence"},{"id":"T12","span":{"begin":1695,"end":1848},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlycoBiology-FMA

    {"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":0,"end":12},"obj":"FMAID:82737"},{"id":"_T2","span":{"begin":0,"end":12},"obj":"FMAID:197276"},{"id":"_T3","span":{"begin":53,"end":69},"obj":"FMAID:50626"},{"id":"_T4","span":{"begin":53,"end":69},"obj":"FMAID:165104"},{"id":"_T5","span":{"begin":73,"end":90},"obj":"FMAID:85434"},{"id":"_T6","span":{"begin":73,"end":90},"obj":"FMAID:199788"},{"id":"_T7","span":{"begin":178,"end":185},"obj":"FMAID:67257"},{"id":"_T8","span":{"begin":178,"end":185},"obj":"FMAID:165447"},{"id":"_T9","span":{"begin":349,"end":356},"obj":"FMAID:146300"},{"id":"_T10","span":{"begin":349,"end":356},"obj":"FMAID:50594"},{"id":"_T11","span":{"begin":420,"end":425},"obj":"FMAID:167330"},{"id":"_T12","span":{"begin":530,"end":547},"obj":"FMAID:199788"},{"id":"_T13","span":{"begin":530,"end":547},"obj":"FMAID:85434"},{"id":"_T14","span":{"begin":666,"end":675},"obj":"FMAID:196789"},{"id":"_T15","span":{"begin":666,"end":675},"obj":"FMAID:82794"},{"id":"_T16","span":{"begin":832,"end":841},"obj":"FMAID:196789"},{"id":"_T17","span":{"begin":832,"end":841},"obj":"FMAID:82794"},{"id":"_T18","span":{"begin":878,"end":890},"obj":"FMAID:82737"},{"id":"_T19","span":{"begin":878,"end":890},"obj":"FMAID:197276"},{"id":"_T20","span":{"begin":956,"end":965},"obj":"FMAID:82794"},{"id":"_T21","span":{"begin":956,"end":965},"obj":"FMAID:196789"},{"id":"_T22","span":{"begin":1033,"end":1047},"obj":"FMAID:196730"},{"id":"_T23","span":{"begin":1033,"end":1047},"obj":"FMAID:82741"},{"id":"_T24","span":{"begin":1077,"end":1086},"obj":"FMAID:82794"},{"id":"_T25","span":{"begin":1077,"end":1086},"obj":"FMAID:196789"},{"id":"_T26","span":{"begin":1103,"end":1120},"obj":"FMAID:196790"},{"id":"_T27","span":{"begin":1103,"end":1120},"obj":"FMAID:82795"},{"id":"_T28","span":{"begin":1204,"end":1213},"obj":"FMAID:196789"},{"id":"_T29","span":{"begin":1204,"end":1213},"obj":"FMAID:82794"},{"id":"_T30","span":{"begin":1276,"end":1281},"obj":"FMAID:196724"},{"id":"_T31","span":{"begin":1319,"end":1324},"obj":"FMAID:196724"},{"id":"_T32","span":{"begin":1596,"end":1601},"obj":"FMAID:196724"},{"id":"_T33","span":{"begin":1709,"end":1718},"obj":"FMAID:196789"},{"id":"_T34","span":{"begin":1709,"end":1718},"obj":"FMAID:82794"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    uniprot-human

    {"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":45,"end":48},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T2","span":{"begin":191,"end":194},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T3","span":{"begin":270,"end":273},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T4","span":{"begin":316,"end":319},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T5","span":{"begin":1458,"end":1461},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T6","span":{"begin":1505,"end":1508},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T7","span":{"begin":1620,"end":1623},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T8","span":{"begin":1690,"end":1693},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T9","span":{"begin":1776,"end":1779},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T10","span":{"begin":167,"end":185},"obj":"http://www.uniprot.org/uniprot/P02741"},{"id":"T11","span":{"begin":45,"end":48},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T12","span":{"begin":191,"end":194},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T13","span":{"begin":270,"end":273},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T14","span":{"begin":316,"end":319},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T15","span":{"begin":1458,"end":1461},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T16","span":{"begin":1505,"end":1508},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T17","span":{"begin":1620,"end":1623},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T18","span":{"begin":1690,"end":1693},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T19","span":{"begin":1776,"end":1779},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T20","span":{"begin":1838,"end":1841},"obj":"http://www.uniprot.org/uniprot/P21291"},{"id":"T21","span":{"begin":420,"end":433},"obj":"http://www.uniprot.org/uniprot/Q86YG0"},{"id":"T22","span":{"begin":549,"end":551},"obj":"http://www.uniprot.org/uniprot/P11498"},{"id":"T23","span":{"begin":590,"end":592},"obj":"http://www.uniprot.org/uniprot/P11498"},{"id":"T24","span":{"begin":755,"end":757},"obj":"http://www.uniprot.org/uniprot/P11498"},{"id":"T25","span":{"begin":1269,"end":1271},"obj":"http://www.uniprot.org/uniprot/P11498"},{"id":"T26","span":{"begin":1444,"end":1446},"obj":"http://www.uniprot.org/uniprot/P11498"},{"id":"T27","span":{"begin":549,"end":551},"obj":"http://www.uniprot.org/uniprot/O00592"},{"id":"T28","span":{"begin":590,"end":592},"obj":"http://www.uniprot.org/uniprot/O00592"},{"id":"T29","span":{"begin":755,"end":757},"obj":"http://www.uniprot.org/uniprot/O00592"},{"id":"T30","span":{"begin":1269,"end":1271},"obj":"http://www.uniprot.org/uniprot/O00592"},{"id":"T31","span":{"begin":1444,"end":1446},"obj":"http://www.uniprot.org/uniprot/O00592"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    uniprot-mouse

    {"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":45,"end":48},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T2","span":{"begin":191,"end":194},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T3","span":{"begin":270,"end":273},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T4","span":{"begin":316,"end":319},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T5","span":{"begin":1458,"end":1461},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T6","span":{"begin":1505,"end":1508},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T7","span":{"begin":1620,"end":1623},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T8","span":{"begin":1690,"end":1693},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T9","span":{"begin":1776,"end":1779},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T10","span":{"begin":1838,"end":1841},"obj":"http://www.uniprot.org/uniprot/P97315"},{"id":"T11","span":{"begin":167,"end":185},"obj":"http://www.uniprot.org/uniprot/P14847"},{"id":"T12","span":{"begin":420,"end":433},"obj":"http://www.uniprot.org/uniprot/P07724"},{"id":"T13","span":{"begin":549,"end":551},"obj":"http://www.uniprot.org/uniprot/Q9R0M4"},{"id":"T14","span":{"begin":590,"end":592},"obj":"http://www.uniprot.org/uniprot/Q9R0M4"},{"id":"T15","span":{"begin":755,"end":757},"obj":"http://www.uniprot.org/uniprot/Q9R0M4"},{"id":"T16","span":{"begin":1269,"end":1271},"obj":"http://www.uniprot.org/uniprot/Q9R0M4"},{"id":"T17","span":{"begin":1444,"end":1446},"obj":"http://www.uniprot.org/uniprot/Q9R0M4"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlycoBiology-NCBITAXON

    {"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":1179,"end":1184},"obj":"http://purl.bioontology.org/ontology/STY/T096"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GO-BP

    {"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":1532,"end":1534},"obj":"http://purl.obolibrary.org/obo/GO_0004306"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GO-MF

    {"project":"GO-MF","denotations":[{"id":"T1","span":{"begin":0,"end":20},"obj":"http://purl.obolibrary.org/obo/GO_0030246"},{"id":"T2","span":{"begin":13,"end":20},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T3","span":{"begin":91,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T4","span":{"begin":649,"end":656},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T5","span":{"begin":768,"end":775},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T6","span":{"begin":813,"end":820},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T7","span":{"begin":852,"end":859},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T8","span":{"begin":900,"end":907},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T9","span":{"begin":935,"end":942},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T10","span":{"begin":1238,"end":1245},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T11","span":{"begin":1325,"end":1332},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T12","span":{"begin":1392,"end":1399},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T13","span":{"begin":1585,"end":1592},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T14","span":{"begin":105,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T15","span":{"begin":1406,"end":1413},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T16","span":{"begin":13,"end":20},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T17","span":{"begin":91,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T18","span":{"begin":649,"end":656},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T19","span":{"begin":768,"end":775},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T20","span":{"begin":813,"end":820},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T21","span":{"begin":852,"end":859},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T22","span":{"begin":900,"end":907},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T23","span":{"begin":935,"end":942},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T24","span":{"begin":1238,"end":1245},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T25","span":{"begin":1325,"end":1332},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T26","span":{"begin":1392,"end":1399},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T27","span":{"begin":1585,"end":1592},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T28","span":{"begin":105,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T29","span":{"begin":1406,"end":1413},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T30","span":{"begin":13,"end":20},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T31","span":{"begin":91,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T32","span":{"begin":649,"end":656},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T33","span":{"begin":768,"end":775},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T34","span":{"begin":813,"end":820},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T35","span":{"begin":852,"end":859},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T36","span":{"begin":900,"end":907},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T37","span":{"begin":935,"end":942},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T38","span":{"begin":1238,"end":1245},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T39","span":{"begin":1325,"end":1332},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T40","span":{"begin":1392,"end":1399},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T41","span":{"begin":1585,"end":1592},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T42","span":{"begin":105,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T43","span":{"begin":1406,"end":1413},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T44","span":{"begin":13,"end":20},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T45","span":{"begin":91,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T46","span":{"begin":649,"end":656},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T47","span":{"begin":768,"end":775},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T48","span":{"begin":813,"end":820},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T49","span":{"begin":852,"end":859},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T50","span":{"begin":900,"end":907},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T51","span":{"begin":935,"end":942},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T52","span":{"begin":1238,"end":1245},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T53","span":{"begin":1325,"end":1332},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T54","span":{"begin":1392,"end":1399},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T55","span":{"begin":1585,"end":1592},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T56","span":{"begin":105,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T57","span":{"begin":1406,"end":1413},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T58","span":{"begin":145,"end":152},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T59","span":{"begin":379,"end":386},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T60","span":{"begin":395,"end":402},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T61","span":{"begin":485,"end":491},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T62","span":{"begin":1319,"end":1332},"obj":"http://purl.obolibrary.org/obo/GO_0030246"},{"id":"T63","span":{"begin":1585,"end":1601},"obj":"http://purl.obolibrary.org/obo/GO_0030246"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    UBERON-AE

    {"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":420,"end":425},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    EDAM-topics

    {"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":0,"end":12},"obj":"http://edamontology.org/topic_0152"},{"id":"T2","span":{"begin":35,"end":40},"obj":"http://edamontology.org/topic_2815"},{"id":"T3","span":{"begin":157,"end":162},"obj":"http://edamontology.org/topic_2815"},{"id":"T4","span":{"begin":178,"end":185},"obj":"http://edamontology.org/topic_0078"},{"id":"T5","span":{"begin":237,"end":252},"obj":"http://edamontology.org/topic_3300"},{"id":"T6","span":{"begin":280,"end":287},"obj":"http://edamontology.org/topic_3678"},{"id":"T7","span":{"begin":308,"end":315},"obj":"http://edamontology.org/topic_0632"},{"id":"T8","span":{"begin":878,"end":890},"obj":"http://edamontology.org/topic_0152"},{"id":"T9","span":{"begin":1343,"end":1351},"obj":"http://edamontology.org/topic_2269"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    EDAM-DFO

    {"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":0,"end":31},"obj":"http://edamontology.org/data_3425"},{"id":"T2","span":{"begin":136,"end":141},"obj":"http://edamontology.org/data_2100"},{"id":"T3","span":{"begin":178,"end":185},"obj":"http://edamontology.org/format_1208"},{"id":"T4","span":{"begin":178,"end":185},"obj":"http://edamontology.org/data_1467"},{"id":"T5","span":{"begin":473,"end":481},"obj":"http://edamontology.org/data_1756"},{"id":"T6","span":{"begin":492,"end":502},"obj":"http://edamontology.org/data_0883"},{"id":"T7","span":{"begin":576,"end":584},"obj":"http://edamontology.org/data_1756"},{"id":"T8","span":{"begin":744,"end":746},"obj":"http://edamontology.org/format_1997"},{"id":"T9","span":{"begin":787,"end":789},"obj":"http://edamontology.org/format_1997"},{"id":"T10","span":{"begin":821,"end":823},"obj":"http://edamontology.org/format_1997"},{"id":"T11","span":{"begin":1033,"end":1047},"obj":"http://edamontology.org/data_2746"},{"id":"T12","span":{"begin":1048,"end":1061},"obj":"http://edamontology.org/data_2726"},{"id":"T13","span":{"begin":1521,"end":1526},"obj":"http://edamontology.org/operation_3454"},{"id":"T14","span":{"begin":1521,"end":1526},"obj":"http://edamontology.org/data_2336"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    Lectin

    {"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":1535,"end":1537},"obj":"https://acgg.asia/db/lfdb/LfDB0344"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlycoBiology-Epitope

    {"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":371,"end":378},"obj":"id"},{"id":"PD-GlycoEpitope-B_T2","span":{"begin":1436,"end":1443},"obj":"id"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    GlyTouCan-IUPAC

    {"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":1276,"end":1281},"obj":"\"http://rdf.glycoinfo.org/glycan/G59665TO\""},{"id":"GlycanIUPAC_T2","span":{"begin":1319,"end":1324},"obj":"\"http://rdf.glycoinfo.org/glycan/G59665TO\""},{"id":"GlycanIUPAC_T3","span":{"begin":1596,"end":1601},"obj":"\"http://rdf.glycoinfo.org/glycan/G59665TO\""},{"id":"GlycanIUPAC_T4","span":{"begin":1276,"end":1281},"obj":"\"http://rdf.glycoinfo.org/glycan/G32915EI\""},{"id":"GlycanIUPAC_T5","span":{"begin":1319,"end":1324},"obj":"\"http://rdf.glycoinfo.org/glycan/G32915EI\""},{"id":"GlycanIUPAC_T6","span":{"begin":1596,"end":1601},"obj":"\"http://rdf.glycoinfo.org/glycan/G32915EI\""},{"id":"GlycanIUPAC_T7","span":{"begin":1276,"end":1281},"obj":"\"http://rdf.glycoinfo.org/glycan/G60625TS\""},{"id":"GlycanIUPAC_T8","span":{"begin":1319,"end":1324},"obj":"\"http://rdf.glycoinfo.org/glycan/G60625TS\""},{"id":"GlycanIUPAC_T9","span":{"begin":1596,"end":1601},"obj":"\"http://rdf.glycoinfo.org/glycan/G60625TS\""},{"id":"GlycanIUPAC_T10","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T11","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T12","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T13","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T14","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T15","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T16","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T17","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T18","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T19","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T20","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T21","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T22","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T23","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T24","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T25","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T26","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T27","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T28","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T29","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T30","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T31","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T32","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T33","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T34","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T35","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T36","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T37","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T38","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T39","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T40","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T41","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T42","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T43","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T44","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T45","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T46","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T47","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T48","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T49","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T50","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T51","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T52","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T53","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T54","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T55","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T56","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T57","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T58","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T59","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T60","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T61","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T62","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T63","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T64","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T65","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T66","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T67","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T68","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T69","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T70","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T71","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T72","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T73","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T74","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T75","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T76","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T77","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T78","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T79","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T80","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T81","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T82","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T83","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T84","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T85","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T86","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T87","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T88","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T89","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T90","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T91","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T92","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T93","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T94","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T95","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T96","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T97","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T98","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T99","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T100","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T101","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T102","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T103","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T104","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T105","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T106","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T107","span":{"begin":1758,"end":1761},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    performance-test

    {"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":420,"end":425},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}

    NCBITAXON

    {"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":35,"end":40},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":157,"end":162},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":413,"end":419},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"9913"}],"text":"Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.\nBinding characteristics of two types of ligands for human neo-C-reactive protein (neo-CRP), which is a conformationally altered but physiologically relevant form of CRP, were studied fluorometrically by probing CRP immobilized on a polystyrene surface with europium-labeled ligands. Two Eu-ligands used were bovine serum albumin derivatives that contain on average 40 residues of ligand structures, one derivative containing phosphorylcholine (PC) and the other lactosyl residues. The PC-containing ligands required the presence of calcium for binding, whereas galactose-containing derivatives bound in the absence of calcium. The optimal pH for the PC-dependent binding was broad (pH 6-8), whereas the best binding pH for the galactose-dependent binding was around 6. The carbohydrate-mediated binding is rather nonspecific: the binding site prefers galactose configuration, but other hexoses can be accommodated. The two best monosaccharide inhibitors at this site were galactose-6-phosphate and galacturonic acid, suggesting the importance of having a negatively charged group at C-6 position of galactose. In fact, the phosphate-binding site is common to both PC and sugar phosphates, and the choline- and the sugar-binding sites are probably located on either side of the phosphate-binding site. Binding characteristics of Eu-labeled PC-BSA to neo-CRP are quite similar to that found for native CRP in solution phase [Lee et al. (2002) J. Biol. Chem., 277, 225-232], whereas binding of sugar phosphates by neo-CRP shows considerably less stringent requirements compared to native CRP. For instance, galactose-alpha1-phosphate was not inhibitory at all in the native CRP binding assay, whereas it was a good inhibitor in the neo-CRP assay."}